• Exchange: Copenhagen
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech


252.4000 DKK 3.2000 1.28%

As of 11:02:32 ET on 10/23/2014.

Snapshot for Genmab A/S (GEN)

Open: 249.0000 Day's Range: 245.7000 - 252.6000 Volume: 224,453
Previous Close: 249.2000 52wk Range: 180.1000 - 260.0000 1-Yr Rtn: +1.86%

Stock Chart for GEN

No chart data available.
  • GEN:DC 252.4000
  • 1D
  • 1M
  • 1Y
Interactive GEN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for GEN

Current P/E Ratio (ttm) 95.8109
Estimated P/E(12/2014) 64.8010
Relative P/E vs. KFX 4.3740
Earnings Per Share (DKK) (ttm) 2.6344
Est. EPS (DKK) (12/2014) 3.8950
Est. PEG Ratio 1.4608
Market Cap (M DKK) 14,341.69
Shares Outstanding (M) 56.82
30 Day Average Volume 206,113
Price/Book (mrq) 8.1740
Price/Sale (ttm) 18.3456
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 11/05/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for GEN

  • Revenue
  • Net Income (M/DKK)
  • Profit Margin (%)

Company Profile & Key Executives for GEN

Genmab A/S is a biotechnology company. The Company creates and develops human antibody products for the treatment of life threatening and debilitating diseases. Genmab focuses on products to treat cancer, rheumatoid arthritis and other inflammatory conditions, and psoriasis. The Company develops new products through partnerships. Genmab operates in Europe and the United States.

Jan G J Van De WinkelPresident/CEO/Co-FounderDavid A EatwellExec VP/CFO
Paul W H I ParrenSenior VP/Dir:ScientificMichael K BauerSenior VP:Clinical Development
More Company Profile & Key Executives for GEN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil